VENUS MEDTECH-B Reports Annual Results: Shareholder Loss Narrows 42.9% to 408 Million Yuan

Stock News03-31

VENUS MEDTECH-B (02500) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 307 million yuan, a decrease of 34.8% compared to the previous year. The loss attributable to owners of the parent company was 408 million yuan, representing a narrowing of 42.9% year-on-year. The basic loss per share was 0.93 yuan.

According to the announcement, all revenue for the reporting period was generated from the sale of medical devices. The company's revenue is primarily derived from six TAVR products currently marketed domestically and internationally: VenusA-Valve, VenusA-Plus, VenusA-Pro, VenusA-Deluxe, Venus-PowerX, and Venus-Vitae. These products are expected to continue to be a significant part of future sales.

The TPVR product, VenusP-Valve, received EU CE MDR certification on April 8, 2022, and was approved for market launch by the NMPA on July 11, 2022. Since its commercialization, it has become a major contributor to the company's overseas revenue.

The fluctuation in revenue was attributed to a decline in both product unit price and sales volume, a result of the intensely competitive market environment in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179334791?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179334791","market":"sh","top_or_hot":-1,"title":"VENUS MEDTECH-B Reports Annual Results: Shareholder Loss Narrows 42.9% to 408 Million Yuan","media":"Stock News","content":"<p>VENUS MEDTECH-B (02500) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 307 million yuan, a decrease of 34.8% compared to the previous year. The loss attributable to owners of the parent company was 408 million yuan, representing a narrowing of 42.9% year-on-year. The basic loss per share was 0.93 yuan.</p>\n<p>According to the announcement, all revenue for the reporting period was generated from the sale of medical devices. The company's revenue is primarily derived from six TAVR products currently marketed domestically and internationally: VenusA-Valve, VenusA-Plus, VenusA-Pro, VenusA-Deluxe, Venus-PowerX, and Venus-Vitae. These products are expected to continue to be a significant part of future sales.</p>\n<p>The TPVR product, VenusP-Valve, received EU CE MDR certification on April 8, 2022, and was approved for market launch by the NMPA on July 11, 2022. Since its commercialization, it has become a major contributor to the company's overseas revenue.</p>\n<p>The fluctuation in revenue was attributed to a decline in both product unit price and sales volume, a result of the intensely competitive market environment in China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VENUS MEDTECH-B Reports Annual Results: Shareholder Loss Narrows 42.9% to 408 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVENUS MEDTECH-B Reports Annual Results: Shareholder Loss Narrows 42.9% to 408 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-31 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VENUS MEDTECH-B (02500) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 307 million yuan, a decrease of 34.8% compared to the previous year. The loss attributable to owners of the parent company was 408 million yuan, representing a narrowing of 42.9% year-on-year. The basic loss per share was 0.93 yuan.</p>\n<p>According to the announcement, all revenue for the reporting period was generated from the sale of medical devices. The company's revenue is primarily derived from six TAVR products currently marketed domestically and internationally: VenusA-Valve, VenusA-Plus, VenusA-Pro, VenusA-Deluxe, Venus-PowerX, and Venus-Vitae. These products are expected to continue to be a significant part of future sales.</p>\n<p>The TPVR product, VenusP-Valve, received EU CE MDR certification on April 8, 2022, and was approved for market launch by the NMPA on July 11, 2022. Since its commercialization, it has become a major contributor to the company's overseas revenue.</p>\n<p>The fluctuation in revenue was attributed to a decline in both product unit price and sales volume, a result of the intensely competitive market environment in China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02500","symbol_name":"启明医疗-B","start_time":0,"source_url":"","article_id":"1179334791","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179334791","pubTimestamp":1774960950,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VENUS MEDTECH-B (02500) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 307 million yuan, a decrease of 34.8% compared to the previous year. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02500":"启明医疗-B","BK1583":"高瓴概念","BK1574":"生物医药B类股","BK1100":"医疗保健设备"},"translate_title":"启明医疗-B公布全年业绩：股东亏损收窄42.9%至4.08亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02500":1},"content_text":"VENUS MEDTECH-B (02500) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 307 million yuan, a decrease of 34.8% compared to the previous year. The loss attributable to owners of the parent company was 408 million yuan, representing a narrowing of 42.9% year-on-year. The basic loss per share was 0.93 yuan.\nAccording to the announcement, all revenue for the reporting period was generated from the sale of medical devices. The company's revenue is primarily derived from six TAVR products currently marketed domestically and internationally: VenusA-Valve, VenusA-Plus, VenusA-Pro, VenusA-Deluxe, Venus-PowerX, and Venus-Vitae. These products are expected to continue to be a significant part of future sales.\nThe TPVR product, VenusP-Valve, received EU CE MDR certification on April 8, 2022, and was approved for market launch by the NMPA on July 11, 2022. Since its commercialization, it has become a major contributor to the company's overseas revenue.\nThe fluctuation in revenue was attributed to a decline in both product unit price and sales volume, a result of the intensely competitive market environment in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179334791","isCrawlerRequest":true}